Nasdaq
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
HeartBeam, Inc. primarily focuses on telemedicine solutions for the detection and monitoring of cardiac disease outside a healthcare facility setting. The company also focuses on providing diagnostic data to physicians with care management of patients with cardiovascular disease.
Roles derived from SEC Form 4 filings.
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$788,000.00 | -$2.3M | -$13.0M | -$15.3M | -$19.9M | -$21.1M |
| Net income | -$1.1M | -$4.4M | -$13.0M | -$14.6M | -$19.4M | -$21.0M |
| Diluted EPS | -$0.29 | -$1.03 | -$1.59 | -$0.72 | -$0.73 | -$0.62 |
| Operating cash flow | -$600,000.00 | -$3.2M | -$9.9M | -$12.1M | -$14.5M | -$14.0M |
| Free cash flow | — | — | -$9.9M | -$12.3M | -$14.7M | -$14.6M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$5.1M | -$5.1M | -$4.9M | -$5.5M | -$5.0M | -$5.3M | -$5.3M | -$4.7M |
| Net income | -$5.0M | -$5.0M | -$4.9M | -$5.5M | -$5.0M | -$5.3M | -$5.3M | -$4.7M |
| Diluted EPS | -$0.19 | -$0.19 | -$0.18 | -$0.18 | -$0.15 | -$0.15 | -$0.14 | -$0.12 |
| Operating cash flow | -$3.5M | -$3.3M | -$4.2M | -$4.5M | -$3.4M | -$3.2M | -$2.9M | -$3.6M |
| Free cash flow | -$3.6M | -$3.4M | -$4.2M | -$4.5M | -$3.5M | -$3.2M | -$3.3M | -$3.9M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Consensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-04-16 | STROME MARK E | Buy | 750,000 | $0.80 | $600,000.00 | filing |
| 2026-04-16 | Elfrink Willhem | Buy | 187,500 | $0.80 | $150,000.00 | filing |
| 2026-04-16 | FERRARI RICHARD M | Buy | 62,500 | $0.80 | $50,000.00 | filing |
| 2026-04-16 | FERRARI RICHARD M | Buy | 57,500 | $0.80 | $46,000.00 | filing |
| 2026-04-16 | JAFF MICHAEL R | Buy | 31,250 | $0.80 | $25,000.00 | filing |
| 2026-04-16 | Cruickshank Tim· CFO | Buy | 31,250 | $0.80 | $25,000.00 | filing |
| 2026-04-16 | Vajdic Branislav | Buy | 31,250 | $0.80 | $25,000.00 | filing |
| 2026-04-16 | Ortigas-Wedekind Marga | Buy | 25,000 | $0.80 | $20,000.00 | filing |
| 2026-04-16 | ENO Robert Paul· President | Buy | 12,500 | $0.80 | $10,000.00 | filing |
| 2026-02-09 | FERRARI RICHARD M | Award | 50,000 | $0.00 | $0.00 | filing |
| 2026-02-09 | JAFF MICHAEL R | Award | 20,689 | $0.00 | $0.00 | filing |
| 2026-02-09 | Nelson Kenneth Warwick III | Award | 17,241 | $0.00 | $0.00 | filing |
| 2025-12-18 | DE URIOSTE GEORGE | Sale | 33,185 | $2.83 | $93,913.55 | filing |
| 2025-12-17 | STROME MARK E | Sale | 250,000 | $3.58 | $895,000.00 | filing |
| 2025-12-17 | DE URIOSTE GEORGE | Sale | 23,961 | $3.68 | $88,176.48 | filing |
Latest 15 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.